High complication rate in Crohn's disease surgery following percutaneous drainage of intra-abdominal abscess: a multicentre study

Introduction Intra-abdominal abscesses complicating Crohn's disease (CD) present an additional challenge as their presence can contraindicate immunosuppressive treatment whilst emergency surgery is associated with high stoma rate and complications. Treatment options include a conservative approach, percutaneous drainage, and surgical intervention. The current multicentre study audited the short-term outcomes of patients who underwent preoperative radiological drainage of intra-abdominal abscesses up to 6 weeks prior to surgery for ileocolonic CD. Methods This is a retrospective, multicentre, observational study promoted by the Italian Society of Colorectal Surgery (SICCR), including all adults undergoing ileocolic resection for primary or recurrent CD from June 2018 to May 2019. The outcomes of patients who underwent radiological guided drainage prior to ileocolonic resection were compared to the patients who did not require preoperative drainage. Postoperative morbidity within 30 days of surgery was the primary endpoint. Postoperative length of hospital stay (LOS) and anastomotic leak rate were the secondary outcomes. Results Amongst a group of 575 included patients who had an ileocolic resection for CD, there were 36 patients (6.2%) who underwent abscess drainage prior to surgery. Postoperative morbidity (44.4%) and anastomotic leak (11.1%) were significantly higher in the group of patients who underwent preoperative drainage. Conclusions Patients with Crohn's disease who require preoperative radiological guided drainage of intra-abdominal abscesses are at increased risk of postoperative morbidity and septic complications following ileocaecal or re-do ileocolic resection

High complication rate in Crohn's disease surgery following percutaneous drainage of intra-abdominal abscess: a multicentre study

Intra-abdominal abscesses complicating Crohn's disease (CD) present an additional challenge as their presence can contraindicate immunosuppressive treatment whilst emergency surgery is associated with high stoma rate and complications. Treatment options include a conservative approach, percutaneous drainage, and surgical intervention. The current multicentre study audited the short-term outcomes of patients who underwent preoperative radiological drainage of intra-abdominal abscesses up to 6 weeks prior to surgery for ileocolonic CD

Long-term results and quality of life in patients treated with hemorrhoidectomy using two different techniques: Ligasure versus transanal hemorrhoidal dearterialization

this study was focused on quality of life of patients treated for hemorroid

Injectable silicone biomaterial (PTQ\u2122) and Hyaluronic Acid for fecal incontinence: a comparative study

this study explain a new technique for this specific diseas

Long-term results and quality of life in patients treated with hemorrhoidectomy using two different techniques: Ligasure versus transanal hemorrhoidal dearterialization

this study was focused on quality of life of patients treated for hemorroid

P422 Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease

Abstract Background Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn’s Disease (CD), is a group of chronic inflammatory disorders. Biologics are indicated for patients failing conventional maintenance therapy with moderate to severe activity. Different routes of administration, intravenous (IV), subcutaneous (SC) or oral have been approved. For chronic diseases such as IBD, some patients may prefer self-administered SC dosing to IV dosing as a less time-intensive and more convenient treatment option. This aims to assess acceptance, safety and satisfaction of transition from IV to SC administration of infliximab (IFX) and vedolizumab (VDZ) in cohort of patients with IBD. Methods The transition from IV to SC administration was proposed to 91 patients. All patients were given two questionnaire: (a) before the switch, focused on the impact of the IV administration on their life and (b) 8 weeks after the switch focused on the level of satisfaction and onset of adverse event (AE). Data on medical history and treatment was collected from electronic health records. Results Overall, 91 patients were enrolled for switching from IV to SC therapy. All patients filled the first questionnaire. The IV therapy did not or minimally burden on patients’ life in 71% and 15 patients (16%) refused the transition. The main reasons why patients preferred to stay on IV administration were the fear of reducing follow-up visit with IBD staff and the fear of doing the therapy outside the hospital. On the other hand, 76 patients accepted and 8 weeks after the transition they completed the second questionnaire. of these 76, 39 CD and 51 male, 41 (53%) were treated with VDZ and the majority of patients (53%) were at the first line of treatment. Most of patients (67%) did not experience any difficulties in handling the device but “only” the 65% respected the correct time-table of administration. 20% of patients report at least one AE, the most common were erythema, swelling and pain in the injection site. Only the 5% should switch back to IV treament. 8 patients (10%) were switched back to IV administration due to AEs and 1 swaped to Ustekinumab. Conclusion In this cohort of IBD patients, we found a good acceptance rate (83.5%). The vast majority of patients (95%) was satisfied of transition from IV to SC. Moreover, we reported a good safety profile of SC therapy, AEs were mostly self-limited and local. </jats:sec

Long term results and quality of life in patients treated with hemorroidectomy using two different techniques: Ligasure vs transanal hemorroidal dearterialization

this study focused on quality of life after treatmen